SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-043736
Filing Date
2023-09-13
Accepted
2023-09-12 21:53:40
Documents
13
Period of Report
2023-09-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20010507x4_8k.htm   iXBRL 8-K 30801
2 EXHIBIT 1.1 ny20010507x4_ex1-1.htm EX-1.1 16965
  Complete submission text file 0001140361-23-043736.txt   187299

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20230912.xsd EX-101.SCH 3877
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20230912_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20230912_pre.xml EX-101.PRE 16052
7 EXTRACTED XBRL INSTANCE DOCUMENT ny20010507x4_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 231251526
SIC: 2834 Pharmaceutical Preparations